Carrageenan is a potent inhibitor of papillomavirus infection

Christopher B Buck, Cynthia D Thompson, Jeffrey N Roberts, Martin Müller, Douglas R Lowy, John T Schiller, Christopher B Buck, Cynthia D Thompson, Jeffrey N Roberts, Martin Müller, Douglas R Lowy, John T Schiller

Abstract

Certain sexually transmitted human papillomavirus (HPV) types are causally associated with the development of cervical cancer. Our recent development of high-titer HPV pseudoviruses has made it possible to perform high-throughput in vitro screens to identify HPV infection inhibitors. Comparison of a variety of compounds revealed that carrageenan, a type of sulfated polysaccharide extracted from red algae, is an extremely potent infection inhibitor for a broad range of sexually transmitted HPVs. Although carrageenan can inhibit herpes simplex viruses and some strains of HIV in vitro, genital HPVs are about a thousand-fold more susceptible, with 50% inhibitory doses in the low ng/ml range. Carrageenan acts primarily by preventing the binding of HPV virions to cells. This finding is consistent with the fact that carrageenan resembles heparan sulfate, an HPV cell-attachment factor. However, carrageenan is three orders of magnitude more potent than heparin, a form of cell-free heparan sulfate that has been regarded as a highly effective model HPV inhibitor. Carrageenan can also block HPV infection through a second, postattachment heparan sulfate-independent effect. Carrageenan is in widespread commercial use as a thickener in a variety of cosmetic and food products, ranging from sexual lubricants to infant feeding formulas. Some of these products block HPV infectivity in vitro, even when diluted a million-fold. Clinical trials are needed to determine whether carrageenan-based products are effective as topical microbicides against genital HPVs.

Conflict of interest statement

Competing interests. The authors have declared that no competing interests exist.

Figures

Figure 1. Polysaccharide Structures
Figure 1. Polysaccharide Structures
Idealized average structures of the disaccharide repeat units of various sulfated polysaccharides. Ac = acetyl, R = [H or SO3 −], R′ = [H, Ac, or SO3 −]. Structures adapted from [13], http://www.lsbu.ac.uk/water/hycar.html, and http://www.sigmaaldrich.com.
Figure 2. Capsid Dose Influences Carrageenan IC…
Figure 2. Capsid Dose Influences Carrageenan IC50
Inhibition assays were performed using a standard dose of GFP-expressing HPV16 PsV in the presence of increasing doses of cold capsids. Overall capsid dose is given as the final concentration of the major capsid protein, L1, in the culture medium.
Figure 3. Capsids Bind Carrageenan
Figure 3. Capsids Bind Carrageenan
Carrageenan beads were incubated with HPV16 or HPV5 capsids in buffers with the NaCl concentration shown. The beads were washed, then bound capsids were eluted and visualized in stained SDS-PAGE gels. Bovine serum albumin (BSA, 65 kDa) was used as a control for nonspecific binding to the beads. For HPV16, an L2 band can be seen above the L1 band.
Figure 4. Standardized Carrageenan IC 50 for…
Figure 4. Standardized Carrageenan IC50 for Various Papillomavirus Types
Points represent carrageenan IC50 of infectivity, except for empty red triangles, which represent the carrageenan IC50 of cell binding for HPV16 capsids covalently linked to a fluorescent dye. Empty circles represent carrageenan IC50 of infectivity observed using HaCaT cells instead of HeLa cells. Error bars represent the 95% CI for the IC50.
Figure 5. Carrageenan Addition Time Course
Figure 5. Carrageenan Addition Time Course
Cells were incubated with HPV16 PsV for 2 h, followed by washout of the virus inoculum. Carrageenan was added at the timepoints shown, where time zero represents initial PsV inoculation.

References

    1. Schiffman M, Kjaer SK. Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr: 14–19; 2003.
    1. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med. 1997;102:3–8.
    1. Manhart LE, Koutsky LA. Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis. Sex Transm Dis. 2002;29:725–735.
    1. Holmes KK, Levine R, Weaver M. Effectiveness of condoms in preventing sexually transmitted infections. Bull World Health Organ. 2004;82:454–461.
    1. Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: A randomized controlled trial. Obstet Gynecol. 2006;107:18–27.
    1. Doorbar J. The papillomavirus life cycle. J Clin Virol. 2005;32((Suppl 1)):S7–S15.
    1. Buck CB, Pastrana DV, Lowy DR, Schiller JT. Efficient intracellular assembly of papillomaviral vectors. J Virol. 2004;78:751–757.
    1. Buck CB, Thompson CD, Pang YY, Lowy DR, Schiller JT. Maturation of papillomavirus capsids. J Virol. 2005;79:2839–2846.
    1. Buck CB, Day PM, Thompson CD, Lubkowski J, Lu W, et al. Human alpha-defensins block papillomavirus infection. Proc Natl Acad Sci U S A. 2006;103:1516–1521.
    1. Joyce JG, Tung JS, Przysiecki CT, Cook JC, Lehman ED, et al. The L1 major capsid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes. J Biol Chem. 1999;274:5810–5822.
    1. Giroglou T, Florin L, Schafer F, Streeck RE, Sapp M. Human papillomavirus infection requires cell surface heparan sulfate. J Virol. 2001;75:1565–1570.
    1. Christensen ND, Reed CA, Culp TD, Hermonat PL, Howett MK, et al. Papillomavirus microbicidal activities of high-molecular-weight cellulose sulfate, dextran sulfate, and polystyrene sulfonate. Antimicrob Agents Chemother. 2001;45:3427–3432.
    1. Esko JD, Selleck SB. Order out of chaos: Assembly of ligand binding sites in heparan sulfate. Annu Rev Biochem. 2002;71:435–471.
    1. Tobacman JK. Review of harmful gastrointestinal effects of carrageenan in animal experiments. Environ Health Perspect. 2001;109:983–994.
    1. Elias CJ, Coggins C, Alvarez F, Brache V, Fraser IS, et al. Colposcopic evaluation of a vaginal gel formulation of iota-carrageenan. Contraception. 1997;56:387–389.
    1. Coggins C, Blanchard K, Alvarez F, Brache V, Weisberg E, et al. Preliminary safety and acceptability of a carrageenan gel for possible use as a vaginal microbicide. Sex Transm Infect. 2000;76:480–483.
    1. Schiffman M, Herrero R, Desalle R, Hildesheim A, Wacholder S, et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology. 2005;337:76–84.
    1. Selinka HC, Giroglou T, Nowak T, Christensen ND, Sapp M. Further evidence that papillomavirus capsids exist in two distinct conformations. J Virol. 2003;77:12961–12967.
    1. Moulard M, Lortat-Jacob H, Mondor I, Roca G, Wyatt R, et al. Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120. J Virol. 2000;74:1948–1960.
    1. Zhang L, Yu W, He T, Yu J, Caffrey RE, et al. Contribution of human alpha-defensin 1, 2, and 3 to the anti-HIV-1 activity of CD8 antiviral factor. Science. 2002;298:995–1000.
    1. Talarico LB, Pujol CA, Zibetti RG, Faria PC, Noseda MD, et al. The antiviral activity of sulfated polysaccharides against dengue virus is dependent on virus serotype and host cell. Antiviral Res. 2005;66:103–110.
    1. De Villiers EM, Fauquet C, Broker TR, Bernard HU, Zur Hausen H. Classification of papillomaviruses. Virology. 2004;324:17–27.
    1. Dvoretzky I, Shober R, Chattopadhyay SK, Lowy DR. A quantitative in vitro focus assay for bovine papilloma virus. Virology. 1980;103:369–375.
    1. Pastrana DV, Vass WC, Lowy DR, Schiller JT. HPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV16. Virology. 2001;279:361–369.
    1. Howett MK, Kuhl JP. Microbicides for prevention of transmission of sexually transmitted diseases. Curr Pharm Des. 2005;11:3731–3746.
    1. Esko JD, Stewart TE, Taylor WH. Animal cell mutants defective in glycosaminoglycan biosynthesis. Proc Natl Acad Sci U S A. 1985;82:3197–3201.
    1. Enomoto Y, Fujii M, Furusho T, Yamamoto N, inventors. Condom coated with acidic polysaccharides. United States patent 5,878,747. inventors; Fuji Latex Co., Ltd., assignee (March 9, 1999)
    1. Hermonat PL, Daniel RW, Shah KV. The spermicide nonoxynol-9 does not inactivate papillomavirus. Sex Transm Dis. 1992;19:203–205.
    1. Gonzalez ME, Alarcon B, Carrasco L. Polysaccharides as antiviral agents: Antiviral activity of carrageenan. Antimicrob Agents Chemother. 1987;31:1388–1393.
    1. Baba M, Snoeck R, Pauwels R, de Clercq E. Sulfated polysaccharides are potent and selective inhibitors of various enveloped viruses, including herpes simplex virus, cytomegalovirus, vesicular stomatitis virus, and human immunodeficiency virus. Antimicrob Agents Chemother. 1988;32:1742–1745.
    1. Lynch G, Low L, Li S, Sloane A, Adams S, et al. Sulfated polyanions prevent HIV infection of lymphocytes by disruption of the CD4-gp120 interaction, but do not inhibit monocyte infection. J Leukoc Biol. 1994;56:266–272.
    1. Zacharopoulos VR, Phillips DM. Vaginal formulations of carrageenan protect mice from herpes simplex virus infection. Clin Diagn Lab Immunol. 1997;4:465–468.
    1. Zeitlin L, Whaley KJ, Hegarty TA, Moench TR, Cone RA. Tests of vaginal microbicides in the mouse genital herpes model. Contraception. 1997;56:329–335.
    1. Witvrouw M, De Clercq E. Sulfated polysaccharides extracted from sea algae as potential antiviral drugs. Gen Pharmacol. 1997;29:497–511.
    1. Maguire RA, Thorn M, Phillips DM, inventors. Carrageenan based antimicrobial compositions. United States Patent Application 2005–0261240. inventors; The Population Council, Inc., assignee; (November 24, 2005)
    1. Patterson NA, Smith JL, Ozbun MA. Human papillomavirus type 31b infection of human keratinocytes does not require heparan sulfate. J Virol. 2005;79:6838–6847.
    1. Culp TD, Budgeon LR, Christensen ND. Human papillomaviruses bind a basal extracellular matrix component secreted by keratinocytes which is distinct from a membrane-associated receptor. Virology. 2006;347:147–159.
    1. Zhang YJ, Hatziioannou T, Zang T, Braaten D, Luban J, et al. Envelope-dependent, cyclophilin-independent effects of glycosaminoglycans on human immunodeficiency virus type 1 attachment and infection. J Virol. 2002;76:6332–6343.
    1. Bobardt MD, Armand-Ugon M, Clotet I, Zhang Z, David G, et al. Effect of polyanion-resistance on HIV-1 infection. Virology. 2004;325:389–398.
    1. Lee JH, Smith RJ. Recurrent respiratory papillomatosis: Pathogenesis to treatment. Curr Opin Otolaryngol Head Neck Surg. 2005;13:354–359.
    1. Sasaki CT, Levine PA, Laitman JT, Crelin ES., Jr. Postnatal descent of the epiglottis in man. A preliminary report. Arch Otolaryngol. 1977;103:169–171.
    1. Winer RL, Koutsky LA. Delivering reassurance to parents: Perinatal human papillomavirus transmission is rare. Sex Transm Dis. 2004;31:63–64.
    1. Pastrana DV, Buck CB, Pang YY, Thompson CD, Castle PE, et al. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology. 2004;321:205–216.
    1. Pastrana DV, Gambhira R, Buck CB, Pang YY, Thompson CD, et al. Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. Virology. 2005;337:365–372.
    1. Shi L, Sanyal G, Ni A, Luo Z, Doshna S, et al. Stabilization of human papillomavirus virus-like particles by non-ionic surfactants. J Pharm Sci. 2005;94:1538–1551.
    1. Bourinbaiar AS, Coleman CF. The effect of gramicidin, a topical contraceptive and antimicrobial agent with anti-HIV activity, against herpes simplex viruses type 1 and 2 in vitro. Arch Virol. 1997;142:2225–2235.
    1. Baghian A, Jaynes J, Enright F, Kousoulas KG. An amphipathic alpha-helical synthetic peptide analogue of melittin inhibits herpes simplex virus-1 (HSV-1)-induced cell fusion and virus spread. Peptides. 1997;18:177–183.
    1. Drobni P, Naslund J, Evander M. Lactoferrin inhibits human papillomavirus binding and uptake in vitro. Antiviral Res. 2004;64:63–68.
    1. Clara A, Manjramkar DD, Reddy VK. Preclinical evaluation of magainin-A as a contraceptive antimicrobial agent. Fertil Steril. 2004;81:1357–1365.
    1. Reddy KV, Yedery RD, Aranha C. Antimicrobial peptides: Premises and promises. Int J Antimicrob Agents. 2004;24:536–547.
    1. Morimoto M, Mori H, Otake T, Ueba N, Kunita N, et al. Inhibitory effect of tachyplesin I on the proliferation of human immunodeficiency virus in vitro. Chemotherapy. 1991;37:206–211.
    1. Higuchi T, Watanabe Y, Waga I. Protein disulfide isomerase suppresses the transcriptional activity of NF-kappaB. Biochem Biophys Res Commun. 2004;318:46–52.
    1. Sandstrom PA, Murray J, Folks TM, Diamond AM. Antioxidant defenses influence HIV-1 replication and associated cytopathic effects. Free Radic Biol Med. 1998;24:1485–1491.
    1. Li M, Beard P, Estes PA, Lyon MK, Garcea RL. Intercapsomeric disulfide bonds in papillomavirus assembly and disassembly. J Virol. 1998;72:2160–2167.
    1. Magnuson B, Rainey EK, Benjamin T, Baryshev M, Mkrtchian S, et al. ERp29 triggers a conformational change in polyomavirus to stimulate membrane binding. Mol Cell. 2005;20:289–300.
    1. Ishikawa A, Kubota Y, Murayama T, Nomura Y. Cell death by 1-chloro-2,4-dinitrobenzene, an inhibitor of thioredoxin reductase and its dual regulation by nitric oxide in rats. Neurosci Lett. 1999;277:99–102.
    1. Glomb-Reinmund S, Kielian M. The role of low pH and disulfide shuffling in the entry and fusion of Semliki Forest virus and Sindbis virus. Virology. 1998;248:372–381.
    1. Doncel GF. Exploiting common targets in human fertilization and HIV infection: Development of novel contraceptive microbicides. Hum Reprod Update. 2006;12:103–117.
    1. Bousarghin L, Touze A, Sizaret PY, Coursaget P. Human papillomavirus types 16, 31, and 58 use different endocytosis pathways to enter cells. J Virol. 2003;77:3846–3850.
    1. Howett MK, Neely EB, Christensen ND, Wigdahl B, Krebs FC, et al. A broad-spectrum microbicide with virucidal activity against sexually transmitted viruses. Antimicrob Agents Chemother. 1999;43:314–321.

Source: PubMed

3
Subscribe